Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ulcerative colitis
Pharma
Delayed FDA nod moves Lilly into crowded ulcerative colitis field
With a new FDA approval, Lilly’s mirikizumab has become the first IL-23 inhibitor to enter the crowded ulcerative colitis field.
Angus Liu
Oct 27, 2023 11:10am
Pfizer wins FDA approval to challenge BMS in ulcerative colitis
Oct 13, 2023 9:36am
Lilly's mirikizumab delivers Crohn's win after FDA rejection
Oct 12, 2023 11:21am
FDA signs off on Takeda's subcutaneous version of Entyvio
Sep 28, 2023 11:32am
Lilly's Omvoh picks up support from England's NICE
Sep 22, 2023 8:25am
BMS starts Women's World Cup ulcerative colitis marketing push
Jul 14, 2023 8:40am